Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190)
Hong Kong
· Delayed Price · Currency is HKD 22.64
+0.04 (0.18%)
Apr 29, 2026, 4:08 PM HKT
HKG:2190 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 1,057 | 782.48 | 527.75 | 334.09 | 177.91 | Upgrade
|
| Revenue Growth (YoY) | 35.15% | 48.27% | 57.97% | 87.78% | 543.88% | Upgrade
|
| Cost of Revenue | 294.57 | 222.58 | 142.77 | 81.42 | 46.03 | Upgrade
|
| Gross Profit | 762.92 | 559.9 | 384.99 | 252.67 | 131.88 | Upgrade
|
| Selling, General & Admin | 315.88 | 265.76 | 277.92 | 249.47 | 195.87 | Upgrade
|
| Research & Development | 246.78 | 233.23 | 261.01 | 233.46 | 168.1 | Upgrade
|
| Other Operating Expenses | 1.45 | 2.1 | 1.6 | -6.78 | -13.94 | Upgrade
|
| Operating Expenses | 564.1 | 501.13 | 540.54 | 476.18 | 350.05 | Upgrade
|
| Operating Income | 198.82 | 58.77 | -155.55 | -223.51 | -218.17 | Upgrade
|
| Interest Expense | -1.02 | -2.18 | -1.25 | -0.72 | -0.31 | Upgrade
|
| Interest & Investment Income | 59.19 | 67.35 | 79.04 | 95.57 | 13.09 | Upgrade
|
| Earnings From Equity Investments | - | -1.1 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -7.16 | 1.51 | -0.26 | 19.63 | -8.28 | Upgrade
|
| Other Non Operating Income (Expenses) | -12.35 | 12.17 | 8.4 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 237.48 | 136.51 | -69.63 | -109.04 | -213.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.65 | -36.21 | -8.51 | 4.81 | 13.95 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.09 | -0.05 | -0.59 | -9.32 | 0.02 | Upgrade
|
| Pretax Income | 236.74 | 100.26 | -78.73 | -113.56 | -199.69 | Upgrade
|
| Income Tax Expense | -7.63 | - | - | - | - | Upgrade
|
| Net Income | 244.37 | 100.26 | -78.73 | -113.56 | -199.69 | Upgrade
|
| Net Income to Common | 244.37 | 100.26 | -78.73 | -113.56 | -199.69 | Upgrade
|
| Net Income Growth | 143.75% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 320 | 323 | 329 | 330 | 295 | Upgrade
|
| Shares Outstanding (Diluted) | 324 | 328 | 329 | 330 | 295 | Upgrade
|
| Shares Change (YoY) | -1.34% | -0.22% | -0.51% | 12.15% | 51.26% | Upgrade
|
| EPS (Basic) | 0.76 | 0.31 | -0.24 | -0.34 | -0.68 | Upgrade
|
| EPS (Diluted) | 0.76 | 0.31 | -0.24 | -0.34 | -0.68 | Upgrade
|
| EPS Growth | 147.04% | - | - | - | - | Upgrade
|
| Free Cash Flow | 273.64 | -17.26 | -92.48 | -226.06 | -194.32 | Upgrade
|
| Free Cash Flow Per Share | 0.85 | -0.05 | -0.28 | -0.68 | -0.66 | Upgrade
|
| Dividend Per Share | 0.220 | 0.100 | - | - | - | Upgrade
|
| Dividend Growth | 120.00% | - | - | - | - | Upgrade
|
| Gross Margin | 72.14% | 71.55% | 72.95% | 75.63% | 74.13% | Upgrade
|
| Operating Margin | 18.80% | 7.51% | -29.48% | -66.90% | -122.63% | Upgrade
|
| Profit Margin | 23.11% | 12.81% | -14.92% | -33.99% | -112.24% | Upgrade
|
| Free Cash Flow Margin | 25.88% | -2.21% | -17.52% | -67.66% | -109.22% | Upgrade
|
| EBITDA | 232.24 | 91.44 | -126.44 | -203.47 | -208.49 | Upgrade
|
| EBITDA Margin | 21.96% | 11.68% | -23.96% | -60.90% | -117.18% | Upgrade
|
| D&A For EBITDA | 33.42 | 32.67 | 29.11 | 20.04 | 9.68 | Upgrade
|
| EBIT | 198.82 | 58.77 | -155.55 | -223.51 | -218.17 | Upgrade
|
| EBIT Margin | 18.80% | 7.51% | -29.48% | -66.90% | -122.63% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.